Novo Nordisk A/S Sponsored ADR (NVO)
Wegovy users have less kidney-related health problems, analysis of Novo study finds
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large study, according to a new analysis the Danish drugmaker published on Saturday.
US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients
A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar.
Ozempic cuts kidney-disease risks, research finds
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
Novo Nordisk's Ozempic slows diabetic kidney disease progression in trial
Novo Nordisk's Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke and death, according to detailed results from a late-stage trial presented on Friday.
US FDA staff flags risk of low blood sugar for Novo Nordisk's weekly insulin
The U.S. Food and Drug Administration's (FDA) staff on Wednesday pointed to "notable imbalance" in incidence of low blood sugar in patients with type 1 diabetes treated with Danish drugmaker Novo Nordisk's long-acting weekly insulin.
Novo Nordisk weight loss drugs still showing upside risk - analyst
Novo Nordisk (NYSE:NVO) A/S' weight loss drug rollout continues to offer scope for upside surprises, Citi analysts have said. Despite ongoing supply constraints, four-week rolling prescription growth for the company's GLP-1-based drugs has soared, analysts said on Monday.
Is Novo Nordisk Stock a Millionaire Maker?
Novo Nordisk's already strong financials could look even better in the future as the company's drugs have loads of potential. The company's high-profit margins make it likely that earnings will soar right along with sales.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
